Literature DB >> 17174370

Pancreatic cancer: pathogenesis, prevention and treatment.

Fazlul H Sarkar1, Sanjeev Banerjee, Yiwei Li.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the United States with a very low survival rate of 5 years. To better design new preventive and/or therapeutic strategies for the fight against pancreatic cancer, the knowledge of the pathogenesis of pancreatic cancer at the molecular level is very important. It has been known that the development and the progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways among which the EGFR, Akt, and NF-kappaB pathways appear to be most relevant. Therefore, the strategies targeting EGFR, Akt, NF-kappaB, and their downstream signaling could be promising for the prevention and/or treatment of pancreatic cancer. In this brief review, we will summarize the current knowledge regarding the pathogenesis, prevention, and treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174370      PMCID: PMC2094388          DOI: 10.1016/j.taap.2006.11.007

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  71 in total

Review 1.  Green tea in chemoprevention of cancer.

Authors:  H Mukhtar; N Ahmad
Journal:  Toxicol Sci       Date:  1999-12       Impact factor: 4.849

Review 2.  Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.

Authors:  Renata Talar-Wojnarowska; Ewa Malecka-Panas
Journal:  Med Sci Monit       Date:  2006-09

3.  Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells.

Authors:  Xian-Zhong Ding; Thomas E Adrian
Journal:  Pancreas       Date:  2002-11       Impact factor: 3.327

4.  Modulation of pancreatic carcinogenesis by antioxidants.

Authors:  R A Woutersen; M J Appel; A Van Garderen-Hoetmer
Journal:  Food Chem Toxicol       Date:  1999 Sep-Oct       Impact factor: 6.023

5.  Vitamin D intake and the risk for pancreatic cancer in two cohort studies.

Authors:  Halcyon G Skinner; Dominique S Michaud; Edward Giovannucci; Walter C Willett; Graham A Colditz; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-09       Impact factor: 4.254

6.  Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Authors:  C J Bruns; M T Harbison; D W Davis; C A Portera; R Tsan; D J McConkey; D B Evans; J L Abbruzzese; D J Hicklin; R Radinsky
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.

Authors:  Susanne Müerköster; Alexander Arlt; Maike Witt; André Gehrz; Sieglinde Haye; Christina March; Frauke Grohmann; Kai Wegehenkel; Holger Kalthoff; Ulrich R Fölsch; Heiner Schäfer
Journal:  Int J Cancer       Date:  2003-04-20       Impact factor: 7.396

8.  Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.

Authors:  Fabienne Vernejoul; Laurent Ghénassia; Anny Souque; Hubert Lulka; Daniel Drocourt; Pierre Cordelier; Lucien Pradayrol; Stéphane Pyronnet; Louis Buscail; Gérard Tiraby
Journal:  Mol Ther       Date:  2006-09-25       Impact factor: 11.454

9.  Function of nuclear factor kappaB in pancreatic cancer metastasis.

Authors:  Shuichi Fujioka; Guido M Sclabas; Christian Schmidt; Wayne A Frederick; Qiang G Dong; James L Abbruzzese; Douglas B Evans; Cheryl Baker; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

10.  Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate.

Authors:  Moriatsu Takada; Yoichiro Nakamura; Tamio Koizumi; Hirochika Toyama; Takashi Kamigaki; Yasuyuki Suzuki; Yoshifumi Takeyama; Yoshikazu Kuroda
Journal:  Pancreas       Date:  2002-07       Impact factor: 3.327

View more
  39 in total

1.  Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.

Authors:  Sanjeev Banerjee; Asfar S Azmi; Subhash Padhye; Marjit W Singh; Jubaraj B Baruah; Philip A Philip; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

2.  Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway.

Authors:  Wei Li; Jiguang Ma; Qingyong Ma; Bin Li; Liang Han; Jiangbo Liu; Qinhong Xu; Wanxing Duan; Shuo Yu; Fengfei Wang; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 3.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Histamine and histamine receptor regulation of gastrointestinal cancers.

Authors:  Lindsey Kennedy; Kyle Hodges; Fanyin Meng; Gianfranco Alpini; Heather Francis
Journal:  Transl Gastrointest Cancer       Date:  2012-10

5.  Effect of soybean oil on atherogenic metabolic risks associated with estrogen deficiency in ovariectomized rats: dietary soybean oil modulate atherogenic risks in overiectomized rats.

Authors:  Hanaa A Hassan; Mosaad A Abdel-Wahhab
Journal:  J Physiol Biochem       Date:  2011-12-29       Impact factor: 4.158

6.  PROFESS: a PROtein function, evolution, structure and sequence database.

Authors:  Thomas Triplet; Matthew D Shortridge; Mark A Griep; Jaime L Stark; Robert Powers; Peter Revesz
Journal:  Database (Oxford)       Date:  2010-07-06       Impact factor: 3.451

7.  Experimental ablation of the pancreas with high intensity focused ultrasound (HIFU) in a porcine model.

Authors:  Biao Xie; Yu-Yuan Li; Lin Jia; Yu-Qiang Nie; Hong Du; Shu-Man Jiang
Journal:  Int J Med Sci       Date:  2010-12-17       Impact factor: 3.738

Review 8.  Diet and supplements and their impact on colorectal cancer.

Authors:  Marinos Pericleous; Dalvinder Mandair; Martyn E Caplin
Journal:  J Gastrointest Oncol       Date:  2013-12

9.  Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.

Authors:  Constantinos Giaginis; Gerasimos Tsourouflis; Adamantia Zizi-Serbetzoglou; Gregorios Kouraklis; Elli Chatzopoulou; Konstantina Dimakopoulou; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2009-12-01       Impact factor: 3.201

10.  Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling.

Authors:  Ming Zhou; Zhenyu Ye; Yizhou Gu; Bian Tian; Bian Wu; Juncheng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.